Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Non-Current Assets (2021 - 2025)

Prime Medicine (PRME) has disclosed Non-Current Assets for 5 consecutive years, with $161.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets rose 88.55% year-over-year to $161.4 million, compared with a TTM value of $637.2 million through Dec 2025, up 79.5%, and an annual FY2025 reading of $161.4 million, up 88.55% over the prior year.
  • Non-Current Assets was $161.4 million for Q4 2025 at Prime Medicine, up from $153.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $164.4 million in Q1 2025 and bottomed at $31.3 million in Q4 2021.
  • Average Non-Current Assets over 5 years is $92.3 million, with a median of $85.6 million recorded in 2024.
  • The sharpest move saw Non-Current Assets skyrocketed 103.65% in 2022, then dropped 20.13% in 2023.
  • Year by year, Non-Current Assets stood at $31.3 million in 2021, then soared by 103.65% to $63.7 million in 2022, then dropped by 20.13% to $50.9 million in 2023, then soared by 68.3% to $85.6 million in 2024, then surged by 88.55% to $161.4 million in 2025.
  • Business Quant data shows Non-Current Assets for PRME at $161.4 million in Q4 2025, $153.6 million in Q3 2025, and $157.7 million in Q2 2025.